Hasan Minhaj sits down with Yale obesity researcher Dr. Ania Jastreboff to dig into how GLP-1 drugs work and whether they live up to the attention.
Recap by typeshit. Full story at Hasan Minhaj.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
The newly published trial tested Lilly's retatrutide in adults with obesity who don't have diabetes. Dr O'Connor calls it another big step for next generation obesity drugs.
A Facebook post says needle-free strip formats are moving from labs toward real use. No product, study or data is named to back it up.
Loading…